People · Operator
Named in public records as an officer, director or promoter · active 2015–2025 · Healthtech, Other Health Care, Robotics, Other, Software / Tech, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Auris Health, Inc. | — | Healthtech | Series D+ | $718.1M | $5.3B | 2015 |
| PROCEPT BioRobotics Corp | — | Other Health Care | Series D+ | $348.8M | $1.6B | 2020 |
| Venus Concept Inc. | — | Other Health Care | Series C | $194.2M | $9.8M | 2019 |
| ShockWave Medical, Inc. | — | Healthtech | Series C | $144.8M | $255.8M | 2018 |
| Avail Medsystems, Inc. | — | Other Health Care | Series C | $126.7M | $2.2B | 2020 |
| MIVI Neuroscience, Inc. | — | Other Health Care | Series C | $67.4M | $4.3M | 2020 |
| EndoQuest Robotics, Inc. | — | Robotics | Series B | $30.7M | $150.1M | 2025 |
| VerAvanti Inc. | — | Other | Series B | $28.9M | $149.5M | 2025 |
| BRIUS Technologies, Inc. | — | Software / Tech | Series B | $21.2M | $109.9M | 2023 |
| Petal Surgical, Inc. | — | Biotechnology | Series B | $17.7M | $77.9M | 2025 |
Frederic Moll at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Frederic Moll on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Frederic H. Moll | 3 | 8 |
| FRED MOLL | 3 | 8 |
| Peter Hebert | 2 | 7 |
| Jay Watkins | 2 | 6 |
| Daniel Hawkins | 2 | 4 |
| James McCollum | 2 | 3 |
| Neeraj Agrawal | 1 | 17 |
| Garheng Kong | 1 | 16 |
| Carter Meyer | 1 | 14 |
| Jack Nielsen | 1 | 13 |
| Ajay Royan | 1 | 13 |
| Craig Taylor | 1 | 13 |
| Amir Abolfathi | 1 | 8 |
| Reza Zadno | 1 | 7 |
| JEFF BIRD | 1 | 7 |
| William Kelley | 1 | 6 |
| ANTOINE PAPIERNIK | 1 | 6 |
| Rodney Perkins | 1 | 6 |
| Robert Stern | 1 | 6 |
| Marc-Andre Marcotte | 1 | 6 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.